CAMBRIDGE, Mass., April 8, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced that members of its scientific teams will be reporting preclinical data from its novel Hedgehog pathway inhibitor program -- an emerging area of cancer research -- during the 2010 American Association of Cancer Research (AACR) Annual Meeting being held in Washington, D.C. from April 17 through April 21, 2010. Infinity's novel Hedgehog pathway inhibitor, IPI-926, is a potent, orally delivered small molecule drug candidate that has demonstrated significant anti-tumor activity in multiple preclinical cancer models. IPI-926 is currently being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors.
The schedule of presentations for Infinity's Hedgehog pathway inhibitor program is as follows:
Tuesday, Apr. 20, 2010: 11:55 a.m. - 12:10 p.m. EDT
Oral Session Title: Hedgehog Pathway in Castration Resistance Prostate Cancer
Presenter: Jennifer Proctor, Infinity Pharmaceuticals
Location: Room 204d
Wednesday, Apr. 21, 2010: 8:00 - 11:00 a.m. EDT
Poster Session Title: The Hedgehog inhibitor IPI-926 inhibits relapse of a non-small cell lung cancer xenograft model following treatment with an EGFR targeted tyrosine kinase inhibitor
Presenter: Everton Mandley, Infinity Pharmaceuticals
Location: Exhibit Hall A-C, Poster Section 8
Wednesday, Apr. 21, 2010: 8:00 - 11:00 a.m. EDT
Poster Session Title: The Hedgehog inhibitor IPI-926 enhances tumor perfusion and nab-paclitaxel activity in a pancreatic xenograft model
Presenter: Veronica Travaglione, Infinity Pharmaceuticals
Location: Exhibit Hall A-C, Poster Section 38
About Infinity Pharmaceuticals, Inc.
Infinity is an innovative drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. Infinity's programs in the inhibition of the Hsp90 chaperone system, the Hedgehog pathway and fatty acid amide hydrolase are evidence of its innovative approach to drug discovery and development. For more information on Infinity, please refer to the company's website at http://www.infi.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include those regarding the utility of Hedgehog pathway inhibition, the therapeutic potential of IPI-926, and the presentation of preclinical data for IPI-926. Such statements are subject to numerous factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that IPI-926 will successfully complete necessary preclinical and clinical development phases or that Infinity's strategic alliance with Mundipharma International Corporation Ltd. will continue for its expected term or that it will fund Infinity's programs as agreed. Management's expectations could also be affected by risks and uncertainties relating to: results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites, and publication review bodies; Infinity's ability to enroll patients in its clinical trials; unplanned cash requirements and expenditures, including in connection with business development activities; and Infinity's ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" included in Infinity's annual report on Form 10-K filed with the Securities and Exchange Commission on March 12, 2010. Any forward-looking statements contained in this press release speak only as of the date hereof, and Infinity expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.